PTGX Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: The Motley Fool

Protagonist (PTGX) Earnings Call Transcript

5 days ago - By: ACCESS Newswire

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

25 days ago - By: Zacks Investment Research - Mentions: ADCT

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

25 days ago - By: ACCESS Newswire

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Zacks Investment Research - Mentions: BOLT

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

a month ago - By: ACCESS Newswire

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

a month ago - By: Benzinga

What 7 Analyst Ratings Have To Say About Protagonist Therapeutics

2 months ago - By: Stocktwits - Mentions: JNJ

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In

a month ago - By: Zacks Investment Research - Mentions: MNKD

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?

a month ago - By: ACCESS Newswire

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

a month ago - By: The Motley Fool - Mentions: GTLS BXS PIPR INDB ...

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million

2 months ago - By: Benzinga

5 Analysts Assess Protagonist Therapeutics: What You Need To Know

3 months ago - By: ACCESS Newswire

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

2 months ago - By: Stocktwits - Mentions: JNJ LEGN

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print

2 months ago - By: Zacks Investment Research - Mentions: JNJ PFE

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal

2 months ago - By: Bloomberg - Mentions: JNJ

Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ

2 months ago - By: ACCESS Newswire

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

3 months ago - By: ACCESS Newswire

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

3 months ago - By: ACCESS Newswire

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

3 months ago - By: ACCESS Newswire

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

3 months ago - By: ACCESS Newswire

PROTAGONIST THERAPEUTICS INC (PTGX) Stock News

PTGX Latest News, Press Relases and Analysis

Protagonist (PTGX) Earnings Call Transcript

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting

What 7 Analyst Ratings Have To Say About Protagonist Therapeutics

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million

5 Analysts Assess Protagonist Therapeutics: What You Need To Know

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal

Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera